PX1 Research provides researchers with analytical-grade CJC-1295 synthesized in ISO 17025-accredited, GMP-compliant USA facilities. Each lot undergoes rigorous third-party verification, including RP-HPLC and mass spectrometry analysis, to guarantee purity exceeding 99% for demanding in vitro and preclinical models.
PX1 Research provides researchers with analytical-grade CJC-1295 synthesized in ISO 17025-accredited, GMP-compliant USA facilities. Each lot undergoes rigorous third-party verification, including RP-HPLC and mass spectrometry analysis, to guarantee purity exceeding 99% for demanding in vitro and preclinical models.
Qualified researchers evaluating vendors for a CJC 1295 sale require transparent analytical documentation, lot-to-lot consistency, and strict chemical purity. CJC-1295 is a synthetic 29-amino-acid peptide analog of growth-hormone-releasing hormone (GHRH) designed to extend plasma half-life and stimulate pulsatile growth hormone secretion in preclinical models.
When acquiring CJC-1295 for in vitro or animal studies, selecting a supplier with verified USA manufacturing and rigorous third-party testing protocols is critical. Substandard research compounds introduce confounding variables, such as residual solvents, truncated peptide sequences, or elevated endotoxin levels, which compromise study reproducibility and invalidate baseline bioassays. At PX1 Research, every batch of CJC-1295 is paired with a downloadable Certificate of Analysis (COA) detailing its physical identity, purity profile, and endotoxin metrics.
CJC-1295 functions as a modified growth-hormone-releasing hormone (GHRH) analog. Structurally derived from the first 29 amino acids of endogenous GHRH (GHRH 1-29), the peptide incorporates strategic amino acid substitutions at positions 2, 8, 15, and 27. These molecular modifications resist enzymatic degradation by dipeptidyl peptidase IV (DPP-IV), significantly extending the biological half-life relative to native GHRH.
In physiological and cellular models, CJC-1295 binds selectively to the GHRH receptor (GHRHR) located on pituitary somatotropes. Receptor activation triggers intracellular cyclic adenosine monophosphate (cAMP) accumulation and protein kinase A (PKA) signaling cascades. Preclinical studies indicate that this mechanism stimulates the synthesis and secretion of endogenous growth hormone (GH) while preserving the natural pulsatile release pattern inherent to intact hypothalamic-pituitary pathways. Browse our full catalog of GHRH analogs to explore complementary secretagogue mechanisms.
In animal models, administration of CJC-1295 demonstrates sustained elevation of both growth hormone and downstream insulin-like growth factor 1 (IGF-1). Unlike native GHRH, which exhibits a rapid clearance half-life measured in minutes, CJC-1295 sustains receptor signaling over extended observation windows without causing receptor downregulation or pituitary exhaustion in preclinical trials.
The sustained release of IGF-1 observed in rodent models is of primary interest in biological research. IGF-1 mediates cellular proliferation, nitrogen retention, and protein synthesis across diverse tissue types. Researchers utilize CJC-1295 to evaluate the downstream transcriptomic and proteomic shifts associated with prolonged axis stimulation, serving as a foundational tool in endocrinology and growth factor research. For broader access to raw analytical materials, view our complete inventory of research peptides.
Preclinical investigation into CJC-1295 spans multiple disciplines, particularly tissue regeneration and metabolic homeostasis. In rodent models of musculoskeletal injury, sustained GH/IGF-1 signaling accelerated fibroblast recruitment, collagen deposition, and satellite cell activation within damaged skeletal muscle tissue.
Furthermore, in vitro and animal assays suggest that GHRH receptor agonists influence lipid oxidation and glucose utilization. By promoting lipolysis in adipocytes while maintaining nitrogen balance in lean tissue, CJC-1295 provides a robust experimental framework for studying metabolic rate regulation, body composition shifts, and cellular repair pathways under controlled laboratory conditions. Investigators interested in broader metabolic research can review related studies in our dedicated research library hub.
Evaluating growth hormone secretagogues requires distinguishing between true GHRH analogs and ghrelin receptor (GHSR-1a) agonists. While GHRH analogs act on pituitary somatotropes via GHRHR, ghrelin mimetic peptides operate through distinct neural and pituitary pathways. Researchers often compare CJC-1295 against related compounds to optimize experimental protocols.
For instance, Sermorelin represents the unmodified 1-29 amino acid sequence of native GHRH, offering a shorter half-life ideal for acute response studies. In contrast, Tesamorelin features a hexenoyl moiety attached to the N-terminus of GHRH, optimized for targeting visceral adipose tissue in specialized preclinical models. When synergistic growth hormone release is required, researchers frequently combine GHRH analogs with selective GHSR agonists like Ipamorelin. This dual-receptor targeting strategy induces a amplified release of GH without elevating systemic cortisol or prolactin levels in animal models.
Assuring chemical integrity is paramount when selecting a vendor for a CJC 1295 sale. PX1 Research adheres to stringent quality control guidelines to ensure that all synthetic peptides meet exact research specifications before distribution.
Every production lot undergoes Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) to establish chemical purity standards exceeding 99%. Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry (MALDI-TOF-MS) or LC-MS is performed to confirm precise molecular mass and sequence alignment. Crucially, chromogenic LAL (Limulus Amebocyte Lysate) assays are conducted to ensure endotoxin levels remain below strict limits (<0.01 EU/mg), eliminating risk of endotoxin-induced inflammatory responses during cell culture assays or animal administration.
CJC-1295 is supplied as a lyophilized (freeze-dried) sterile powder to ensure long-term chemical stability. Upon arrival, unopened vials should be stored in a freezer at -20°C or -80°C, protected from light and moisture. Under these conditions, the lyophilized peptide remains stable for up to 24 months.
For laboratory reconstitution, researchers should use sterile bacteriostatic water or target-appropriate buffer solutions under a laminar flow hood. Gently introduce the solvent down the glass wall of the vial to avoid agitating the peptide matrix, allowing it to dissolve completely without vigorous shaking. Once reconstituted, liquid solutions should be kept refrigerated between 2°C and 8°C and utilized within 30 days. Avoid repeated freeze-thaw cycles, as physical shear forces can cause peptide denaturation and loss of biological activity.
PX1 Research is an established supplier of reference-grade research peptides, catering to university laboratories, contract research organizations (CROs), and independent biotechnology institutions. Our commitment to quality control ensures that your laboratory receives consistent, unadulterated compounds for reproducible data collection.
Key advantages of sourcing CJC-1295 through PX1 Research include:
• USA-based synthesis within state-of-the-art, GMP-compliant facilities.
• Lot-specific COAs independently verified by ISO 17025-accredited analytical laboratories.
• Guaranteed purity thresholds strictly verified by RP-HPLC and mass spectrometry.
• Ultra-low endotoxin validation for sensitive cell culture and animal studies.
• Express, same-day shipping on orders placed Monday through Friday, dispatched directly from our regional fulfillment centers in California and Arizona.
Institutional laboratories requiring bulk volume or recurring supply agreements can access custom pricing through our dedicated wholesale program.
What is CJC-1295 used for in laboratory research?
CJC-1295 is studied in preclinical settings as a synthetic GHRH analog. Researchers utilize it to investigate growth hormone stimulation, IGF-1 expression, tissue repair dynamics, nitrogen retention, and metabolic pathways in cell cultures and animal models.
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with Drug Affinity Complex (DAC) includes a maleimido derivative that covalently binds to circulating albumin, significantly extending its half-life to several days in animal models. CJC-1295 without DAC (often referred to as Modified GRF 1-29) lacks this complex, resulting in a shorter half-life more comparable to physiological GHRH pulses.
How does PX1 Research verify the purity of CJC-1295?
PX1 Research subjects every batch of CJC-1295 to independent third-party testing at ISO 17025-accredited laboratories. Purity is validated via RP-HPLC, molecular mass is confirmed using LC-MS, and safety for bioassays is verified through LAL endotoxin testing.
What solvent should be used to reconstitute lyophilized CJC-1295?
For standard laboratory procedures, CJC-1295 is typically reconstituted using sterile bacteriostatic water (0.9% benzyl alcohol) or laboratory-grade sterile saline, depending on the requirements of the specific in vitro or in vivo study protocol.
How should reconstituted CJC-1295 be stored in the lab?
Once reconstituted into solution, CJC-1295 should be stored in a laboratory refrigerator at 2°C to 8°C and protected from light. Reconstituted aliquots should be used within 30 days and kept free of repeated freeze-thaw cycles.
Does PX1 Research ship CJC-1295 internationally?
PX1 Research primarily serves domestic academic and private laboratory facilities within the United States. All domestic orders ship same-day from our California and Arizona fulfillment centers when placed Monday through Friday.
Is CJC-1295 approved for human consumption or therapeutic use?
No. CJC-1295 sold by PX1 Research is strictly intended for laboratory research use only (RUO). It is not approved for human or veterinary use, medical diagnosis, treatment, or therapeutic administration.
Can CJC-1295 be co-administered with other growth hormone secretagogues in research?
Yes, in preclinical studies, researchers frequently co-administer GHRH analogs like CJC-1295 with GHRPs or ghrelin receptor agonists (such as Ipamorelin) to analyze synergistic growth hormone pulse amplification across dual signaling pathways.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.